Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. He is co-founder of a number of biotech companies and is an active board member in several of Aglaia’s portfolio companies. Before founding Aglaia Oncology Funds in 2003, he was Program Director of the NDDO Research Foundation. He held several positions with NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002) and was secretary of the Dutch Society of Gene Therapy. From 1993 until 1997 Mark was Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993. In this period he organized and managed a European concerted action “Immunology of human papillomaviruses and vaccine development”, also being the topic of his PhD thesis, which he defended at the University of Utrecht in 1996.Specialties: Biomedical venturing, Anti-cancer drug development,